Small Cell Lung Cancer With de novo BRAF V600E Mutation and Durable Response to Targeted Therapy: A Case Report

Abstract

• •
  Small Cell Lung Cancer (SCLC) is rare in those without a history of smoking, underscoring the importance of a thorough smoking history assessment.
• •
  While rare, targetable genetic alterations can occur in SCLC, necessitating comprehensive molecular profiling in select cases.
• •
  Next generation sequencing should be considered for SCLC patients without a smoking history to identify potentially actionable mutations.
• •
  When targetable genetic alterations are detected, a trial of therapy with targeted inhibitors is reasonable, albeit with the understanding that outcomes are typically not promising.